Stay updated on Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial

Sign up to get notified when there's something new on the Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    Revision v3.4.3 was added and Revision v3.4.2 was removed from the version history.
    Difference
    0.0%
    Check dated 2026-03-12T00:29:16.000Z thumbnail image
  2. Check
    12 days ago
    No Change Detected
  3. Check
    20 days ago
    No Change Detected
  4. Check
    34 days ago
    Change Detected
    Summary
    Revision: v3.4.2 added to the history and the preceding notices about government funding lapse and operating status (v3.4.1) were removed. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.3%
    Check dated 2026-02-11T11:15:08.000Z thumbnail image
  5. Check
    41 days ago
    Change Detected
    Summary
    A site-wide funding notice was added, and the page revision was updated from v3.4.0 to v3.4.1.
    Difference
    0.3%
    Check dated 2026-02-04T06:31:47.000Z thumbnail image
  6. Check
    48 days ago
    Change Detected
    Summary
    Additions include Show glossary / Hide glossary controls and color-coded highlights for additions and deletions, plus the new revision note v3.4.0. Deletions remove the No FEAR Act data label and the prior revision note v3.3.4.
    Difference
    0.5%
    Check dated 2026-01-28T04:30:42.000Z thumbnail image
  7. Check
    62 days ago
    Change Detected
    Summary
    On 2026-01-07, Contacts/Locations and Study Status were added (revision v3.3.4). On 2025-12-15, revision v3.3.3 was deleted.
    Difference
    0.2%
    Check dated 2026-01-14T02:56:07.000Z thumbnail image
  8. Check
    84 days ago
    Change Detected
    Summary
    Added a footer note 'Revision: v3.3.3' and removed 'HHS Vulnerability Disclosure' and 'Revision: v3.3.2' from the footer. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2025-12-23T17:17:07.000Z thumbnail image

Stay in the know with updates to Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial page.